Knee Cartilage LesionsNCT07542184
Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Panama
A study testing Nanochon Chondrograft in people with Knee Cartilage Lesions, run by Nanochon, Inc. at 1 site in Panama.
Trial summary
The goal of this First in Human study is to learn if the Nanochon Chondrograft Implant is a safe primary surgical treatment for participants with cartilage lesions in the knee. This study will include males and females between the ages of 22 and 60. Read more about this study
- Who is it for?
- Ages 22 to 60 years
- Conditions the study is for
- Knee Cartilage Lesions
- What is being tested?
- Nanochon Chondrograft
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 sitePanama
- Study dates
- 30 Jul 2026to Sep 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male or female ≥22 years and ≤ 60 years of age
- MRI knee evaluation completed within 6 months prior to enrollment
- Participant must be able to read and speak English and/or Spanish
- Participant must voluntarily sign the REB approved informed consent form (ICF)
Who cannot join
- Any known systemic cartilage and/or bone disorder, such as, but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta
- Requires bilateral knee surgery
- Pregnancy, planning to become pregnant or breast feeding
- Any significant illness (metastasis cancer of any type) that decreases the probability of the participant's survival to 12 months
- Known insulin dependent diabetes mellitus
- Steroid treatment (oral or IV) within the past 6 months
Show all 17Show fewer
- Participant is:
- receiving workman's compensation
- receiving prescription narcotic medication
- active with litigation relating to musculoskeletal injuries or disorders
- a prisoner or pending incarceration
- Comorbidities that could impact study participation or results (e.g., autoimmune disorder, HIV, neuropathic pain or fibromyalgia, restless leg syndrome, active infection, or pain requiring chronic pain management), in the opinion of the investigator at the time of enrollment
- Significant psychiatric disorders (e.g., major depression, anxiety disorders, bipolar disorder, and schizophrenia)
- Substance and/or alcohol dependence and/or abuse based on clinical history, physical exam and participant presentation
- Current participation in another drug or device study that, in the opinion of the investigator at the time of enrollment, would interfere with participation in this study
- Participant has claustrophobia or implanted metallic devices (e.g., cardiac pacemakers, insulin pumps, nerve stimulators), medically implanted clips or other electronically, magnetically or mechanically activated implants that would contraindicate undergoing an MRI
- Known allergy or hypersensitivity to any investigational device materials.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Panama1 site, 1 recruiting
- Recruiting
The Panama Clinic
Panama City, Provincia de Panamá
Allissan Study Coordinator, MD, +507 310-1111, aorobio@thepanamaclinic.com
Juan Osorio, MD
About this study
Official title: A First in Human (FIH) Early Feasibility Study (EFS) to Evaluate the Safety and Performance of the Nanochon Chondrograft™ Implant for Re-surfacing of Cartilage Lesions
The goal of this First in Human study is to learn if the Nanochon Chondrograft Implant is a safe primary surgical treatment for participants with cartilage lesions in the knee. This study will include males and females between the ages of 22 and 60.
- Conditions
- Knee Cartilage Lesions
- Being tested
- Nanochon Chondrograft
- Keywords
- Knee cartilage lesions, Medial femoral condyle lesion, Lateral femoral condyle lesion, Trochlea articular cartilage lesion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nanochon ChondrograftDevice
Also called Chondrograft
Mini arthrotomy or arthroscopic surgical implantation of Nanochon Chondrograft
| Study group | Role | What they receive |
|---|---|---|
| Nanochon Chondrograft | Experimental | Mini arthrotomy or arthroscopic surgical implantation of Nanochon Chondrograft Receives: Device: Nanochon Chondrograft |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serious Adverse Device Effects
Absence of Serious Adverse Device Event Effects (SADEs) through Month 12
Measured: Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2026
- Study start30 Jul 2026
- Primary completionSep 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee Cartilage LesionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 5 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nanochon, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07542184
- Sponsor's protocol ID
- 101-2024 - PAN
- Status last verified
- Aug 2026
- First submitted
- 14 Apr 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Undecided at this time.